Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.00 -0.94% 630.00 630.00 636.00 636.00 632.00 632.00 18,989 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 241

International Biotechnol... Share Discussion Threads

Showing 176 to 193 of 500 messages
Chat Pages: Latest  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
20/12/2010
15:47
Intl. Biotechnology Trust PLC 17 December 2010 INTERNATIONAL BIOTECHNOLOGY TRUST PLC Portfolio Update as at 30 November 2010 Total net assets GBP99.4m NAV per share 166.3p Share price 137.0p Total value of unquoted investments GBP23.3m Total number of portfolio companies 60 Cash 1% NAV Cash committed and reserved to 9% NAV unquoted investments Portfolio companies with < 1 year 10% NAV of cash Top Ten Holdings Company Name % NAV Celgene 5.80 Micromet 5.77 Amgen 5.30 Shire Ltd 5.16 Gilead Sciences 4.83 Alexion Pharmaceuticals 3.54 Teva 3.43 Insulet 3.39 Genzyme 3.27 Cadent 3.25 ----------- Total 43.74 Geographical Allocation % United States 74 Europe 23 Australia 2 Cash 1 ----------- Total 100 Quoted/Unquoted allocation % Quoted 76 Unquoted 23 Cash 1 ----------- Total 100
davebowler
03/11/2010
09:29
Edison note; During the 12 months to 31 August 2010 International Biotechnology Trust (IBT) underperformed the NASDAQ Biotechnology Index (NASBIOT) – large cap biased by 4.2% in terms of NAV total return, but outperformed Russell 2000 Biotechnology Growth Index (R2BIOG) – small cap biased by 11.5%. In terms of share price total return, IBT outperformed the NASBIOT by 4.2% and the R2BIOG by 19.9%. The superior share price performance, over the NAV, reflects a narrowing of the discount during the period. The manager considers that biotech has suffered from substantial negative sentiment during the last year and investors' appetite for risk is much diminished. The manager expects that, as this returns, valuations will move up from their current historic lows offering significant upside potential. International Biotechnology Trust aims to achieve long-term capital growth by investing in development stage biotechnology companies that are either quoted or unquoted with the potential for high growth.
davebowler
03/11/2010
08:32
New note - http://www.stockopedia.co.uk/research/international-biotech-lonibt-recovery-potential-50097/
yespmedc
21/7/2010
15:37
The Manager of BIOG's views; biotech will be a net beneficiary of healthcare reform; the regulatory environment will continue to improve; M&A activity will continue at a steady pace; and, in P/E terms, biotech valuations are at 15-year lows. As such, the outlook for the sector is positive.
davebowler
08/6/2010
12:55
THE BIOTECH GROWTH TRUST PLC is on a 4% discount to assets yet this is at a 18% discount -crazy!
davebowler
08/6/2010
12:17
http://www.fundstrategy.co.uk/features/trends/new-era-promises-a-sweeter-pill/1012893.article
davebowler
30/4/2010
10:09
The Board of International Biotechnology Trust plc (the "Company") notes that Gold Medal Acquisitions UK Limited has made a bid for the AIM listed company Fulcrum Pharma Plc (Ticker: LON:FUL). The Company has committed up to £1.3m to the funding of a new investment in Gold Medal Acquisitions UK limited were it to be successful in its bid.
davebowler
21/4/2010
11:35
http://www.internationalbiotrust.com/reports/IBTInterim2010.pdf
davebowler
17/4/2010
19:19
From the Times; IBT Vectura, Vernalis, and now Antisoma - the roster of British biotechnology stocks to have disappointed investors grows by the day. Which is why International Biotechnology Trust, a London-listed closed-end fund, may appeal to those seeking a lower-risk entry to this high-risk niche. First, it provides diversification, spreading its bets between 58 companies, rather than one. Second, only 10 per cent of IBT's funds are invested in the perenially underperforming UK - much of them in Shire, a long-term holding. Instead, it has 80 per cent of its capital in the US, where it is exposed to both the sector's stalwarts, such as Amgen and Genzyme, and up-and-coming mid-caps that might pass the amateur by - Micromet, the cancer specialist that is its biggest holding, being a prime example. Finally, through its relationship with SV Life Science, IBT has 20 per cent of its £110 million portfolio tied up in unquoted companies, which private investors are unable to access. Yesterday's first-half figures show IBT continues to deliver increases in net asset value (NAV) - up 8 per cent to 164p in the six months to March 31. Helped by clarity over US healthcare reforms, and a Japanese hostile bid for OSI, one of its holdings, NAV has since risen further - to 178p. The case from here is that half a dozen of IBT's big American stocks, such as Celgene and Vertex, will report important trial results in 2010. Meanwhile, its unquoted portfolio is now of a suffient maturity to start providing an exit. Above all, American biotech stocks, at 14 times earnings, remain inexpensive - even more so given that, at 139¾p, IBT sits at a 22 per cent discount to NAV, and will benefit from sterling weakness. Buy.
davebowler
24/3/2010
13:41
still trading 40 odd p below nav
shiptoshaw
03/3/2010
13:11
This thread includes charts etc
davebowler
09/2/2010
13:12
http://www.internationalbiotrust.com/fact_sheets/2009/January%202010.pdf
davebowler
13/11/2008
12:09
romi2nikki1...........It is a puzzle why the IBT share price has not responded to the recent increase in NAV. The company has declared an objective of maintaining the discount at no greater than 8%. To that end, they have recently bought back 5% of the shares into treasury at 20% discount. In addition, they do not hedge currency. Ongoing depreciation of GBP against USD is offsetting significantly any fall in underlying US asset values. Two good reasons to expect a correction.
foster
12/11/2008
20:48
Discount seems wide on historical basis, and considerably wider than discount on the Frostrow Trust ( biog). Biog much more volatile range, whereas a steady widening IBT. Consider that it is because IBT holds much more unquoted, but as long been the case. Excellent detail on IBT site, much more detail on pipeline progression and cashburn of holdings.
romi2nikki1
23/1/2007
21:33
see http://www.investorwords.com/5431/C_shares.html seems A shares incur a buying fee, B shares a selling fee & C shares an ongoing charge - which I'd have thought applied to most IT's prospectus http://www.internationalbiotrust.com/press_releases/issue_equity.pdf esp end page 2, & 3 take it the C shares will be invested separately then the portfolios combined in ratio to the NAV's achieved can see the point of the offer to raise cash DYOR & NAI!!
gurp
16/1/2007
20:34
Can anybody help me .What is a C share?
21up
13/11/2006
09:34
unfortunately now at a slight premium to nav, small bios in vogue with large pharmas looking for new products
gurp
11/10/2006
16:56
Information needed.Is MW talking about IBT?Thanks
21up
Chat Pages: Latest  8  7  6  5  4  3  2  1
Your Recent History
LSE
IBT
Internatio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191207 06:16:25